The effective date for a Genetic Testing in Oncology: Specific Test Local Coverage Determination (LCD) by Medicare in the US has been extended by two months to April 24, 2025.
The change was discovered after an off-schedule update to the Medicare Coverage Database.
Dunedin-based cancer diagnostics company, Pacific Edge has been lobbying to overturn or withdraw the determination, which would leave its Cxbladder cancer detection tool without public cover in the US.
Pacific Edge said it will provide further updates to shareholders as more information becomes available.
See more
